Archive: 03/06/2019
Suggested benefit in PCV chemoradiotherapy for both IDH-mutant WHO-defined molecular subgroups
A recent, updated predictive analysis of the three WHO-defined molecular subgroups based on isocitrate dehydrogenase 1/2 (IDH) mutation status and 1p/19q co-deletion status represented in the high-risk treatment arms of the ...
Jun 3, 2019
Trial sets new standard regimen for women with uterine carcinosarcomas
Results from the phase III NRG Oncology clinical trial GOG 0261 comparing paclitaxel plus carboplatin (PC) to paclitaxel plus ifosfamide (PI) in women with stage I-IV, recurrent carcinosarcoma of the uterus or ovary, indicate ...
Jun 3, 2019
Patients who received PBI without chemotherapy experienced less fatigue, slightly poorer cosmesis
Patient-reported outcome (PRO) data indicates that partial breast irradiation (PBI) is more convenient than whole breast irradiation (WBI) for women with breast cancer who do not receive adjuvant chemotherapy. These participants ...
Jun 3, 2019